Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27224954 | 0.92 | DRD2 (0.59) | DRD2KMT2AMEN1KCNA3SMN1; SMN2 | |
| SCHEMBL30750698 | 0.92 | L3MBTL1 (0.52) | DRD2KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL951538 | 0.92 | KMT2A (0.59) | KMT2AMEN1KCNA3SMN1; SMN2NPC1 | |
| SCHEMBL30965777 | 0.87 | SMN1; SMN2 (0.49) | DRD2SMN1; SMN2NPC1RAB9AGRIN2B | |
| SCHEMBL30981426 | 0.87 | HSD11B1 (0.52) | DRD2KMT2AMEN1KCNA3L3MBTL1 | |
| SCHEMBL25313129 | 0.86 | SMN1; SMN2 (0.52) | DRD2KMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL25313131 | 0.86 | SMN1; SMN2 (0.52) | DRD2KMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL6590981 | 0.86 | SMN1; SMN2 (0.58) | KMT2AMEN1KCNA3SMN1; SMN2NPC1 | |
| SCHEMBL2744899 | 0.86 | KMT2A (0.53) | KMT2AMEN1KCNA3SMN1; SMN2NPC1 | |
| SCHEMBL6590294 | 0.86 | DRD2 (0.56) | DRD2KMT2AKCNA3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| CN-113784969-A | PLK1 Selective degradation inducing Compounds | 厄普特拉公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-1653063-A | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofurylcarbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, and method for producing the same, pharmaceutical composition containing the same and i | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-08-10 | — | — | CN | disclosed |
| EP-1076055-B1 | 1- (1-SUBSTITUTED-4-PIPERIDINYL)METHYL]-4-PIPERIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES OF THESE COMPOUNDS | DAINIPPON PHARMACEUTICAL CO (JP) | 2004-11-24 | — | — | EP | disclosed |
| EP-1362857-B1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | DAINIPPON PHARMACEUTICAL CO (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-6696468-B2 | GASTROINTESTINAL MOTILITY ENHANCER OR PROKINETIC AGENT; AFFINITY FOR 5-HT4 RECEPTOR; REDUCED SIDE EFFECTS TO HEART OR CENTRAL NERVOUS SYSTEM | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| EP-1362857-A1 | (S)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinymethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-6294555-B1 | SEROTONIN HT3 RECEPTOR ANTAGONIST FOR GASTROINTESTINAL DISORDERS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-09-25 | — | — | US | disclosed |
| EP-1076055-A1 | 1- (1-SUBSTITUTED-4-PIPERIDINYL)METHYL]-4-PIPERIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES OF THESE COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 2001-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | DRD2 3885/4885KMT2A 928/4885MEN1 1845/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | DRD2 3885/4885KMT2A 928/4885MEN1 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.